<DOC>
	<DOCNO>NCT01407900</DOCNO>
	<brief_summary>The overall aim conduct human physiologic study assess renal neurohumoral effect CD-NP v placebo old subject stable chronic systolic heart failure moderate renal dysfunction .</brief_summary>
	<brief_title>Effects Chimeric Natriuretic Peptide Versus Placebo Stable Heart Failure Moderate Renal Dysfunction</brief_title>
	<detailed_description>The investigator evaluate renal neurohumoral effect dual receptor ( NPR-A NPR-B ) activation CD-NP . This clinically relevant patient population increase risk develop diuretic resistance treatment HF exacerbation .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Male nonpregnant female stable chronic HF primary cardiac etiology , rest leave ventricular ejection fraction ( LVEF ) ≤ 40 % document within last 2 year . Moderate renal dysfunction creatinine clearance 3060 ml.min1.1.73m2 , calculate CockcroftGault formula24 adjust body surface area within past year screening , requirement dialysis . Be willing provide inform consent . Known allergy adverse reaction exogenous natriuretic peptide ( CDNP component , nesiritide , natriuretic peptide , related compound ) . Women pregnant , breastfeeding , hormonal contraceptive hormone replacement therapy . ( Women postmenopausal state , define absence menses ≥ 1 year serum folliclestimulating hormone ≥ 20 IU/L ; previously sterilize defined bilateral tubal occlusion ≥ 6 month , bilateral oophorectomy , complete hysterectomy ) Having receive nesiritide within 7 day prior prior entry study . Having receive investigational drug device within 30 day prior entry study . Clinically unstable patient ( e.g . systolic blood pressure &lt; 90 mmHg , ongoing requirement vasopressor mechanical circulatory support , mechanical ventilation ) . Recent hospitalization decompensated HF recent defibrillation cardiac resuscitation within 30 day prior randomization . Prior organ transplantation , wait list organ transplantation , ongoing requirement longterm vasoactive support . Prior requirement dialysis ultrafiltration Active urinary tract infection Patients guard prognosis unlikely derive meaningful benefit CDNP . Use sulfonamide , nonsteroidal antiinflammatory drug , probenecid , drug know alter renal function within one week first dose CDNP placebo . Presence cardiac lesion comorbidities may contraindicate use natriuretic peptide , clinically significant cardiac valvular stenosis , hypertrophic cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , uncorrected congenital heart disease contraindicates use vasodilator . History blood pressure &gt; 190/115 mmHg unexplained syncope within past 3 month . Symptomatic carotid artery disease , know critical carotid stenosis , stroke within past 3 month Clinically significant renal artery stenosis Baseline hemoglobin &lt; 10.0 g/dl . Serum sodium &lt; 130 mEq/L , potassium &lt; 3.6 mEq/L , magnesium &lt; 1.7 mEq/L . Elevated aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) least 5 time upper limit normal bilirubin least 3 time upper limit normal History alcohol abuse within past 6 month . Consumption phosphodiesterase5 inhibitor ( sildenafil , vardenafil , tadalafil ) within 72 hour receive CDNP placebo . Inability communicate effectively study personnel . BMI &gt; 38</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>CD NP</keyword>
	<keyword>dual receptor</keyword>
	<keyword>NPR A</keyword>
	<keyword>NPR B</keyword>
	<keyword>Adult , age 45</keyword>
</DOC>